EconPapers    
Economics at your fingertips  
 

Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine

Mike Paulden (), James F. O’Mahony () and Christopher McCabe ()
Additional contact information
Mike Paulden: University of Alberta
James F. O’Mahony: Trinity College Dublin
Christopher McCabe: University of Alberta

PharmacoEconomics, 2017, vol. 35, issue 1, No 2, 5-13

Abstract: Abstract Twenty years ago, the “Panel on Cost-effectiveness in Health and Medicine” published a landmark text setting out appropriate methods for conducting cost-effectiveness analyses of health technologies. In the two decades since, the methods used for economic evaluations have advanced substantially. Recently, a “second panel” (hereafter “the panel”) was convened to update the text and its recommendations were published in November 2016. The purpose of this paper is to critique the panel’s updated guidance regarding the discounting of costs and health effects. The advances in discounting methodology since the first panel include greater theoretical clarity regarding the specification of discount rates, how these rates vary with the analytical perspective chosen, and whether the healthcare budget is constrained. More specifically, there has been an important resolution of the debate regarding the conditions under which differential discounting of costs and health effects is appropriate. We show that the panel’s recommendations are inconsistent with this recent literature. Importantly, the panel’s departures from previously published findings do not arise from an alternative interpretation of theory; rather, we demonstrate that this is due to fundamental errors in methodology and logic. The panel also failed to conduct a formal review of relevant empirical evidence. We provide a number of suggestions for how the panel’s recommendations could be improved in future.

Keywords: Discount Rate; Incremental Cost; Marginal Utility; Time Preference; Future Consumption (search for similar items in EconPapers)
Date: 2017
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://link.springer.com/10.1007/s40273-016-0482-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:35:y:2017:i:1:d:10.1007_s40273-016-0482-0

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-016-0482-0

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-20
Handle: RePEc:spr:pharme:v:35:y:2017:i:1:d:10.1007_s40273-016-0482-0